SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic ...

Fam-trastuzumab deruxtecan-nxki significantly improved outcomes compared with chemotherapy among patients with HER2-positive gastric cancer, according to study results presented during the ASCO20 ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

About [Fam]-trastuzumab deruxtecan [Fam]-trastuzumab deruxtecan, (DS-8201), is the lead product in the investigational ADC Franchise of the Daiichi Sankyo Cancer Enterprise and the most advanced ...

Background: The Destiny-03 trial observed that a median progression-free survival was not reached in the patients (pts) treated with fam-trastuzumab deruxtecan-nxki (TDxd) and was 6.8 months in the ...

WILMINGTON, Del., May 07, 2025--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is a prescription drug. It treats breast cancer in females and males. Learn about side effects, dosage, how it’s given, and more.

Ado-trastuzumab Emtansine is used to treat HER2-positive metastatic breast cancer, a specific type of breast cancer that has moved to other parts of the body.

Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo’sENHERTU ® (fam-trastuzumab deruxtecan-nxki) met the ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated ...

WILMINGTON, Del., January 27, 2025--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or ...

AstraZeneca and Daiichi Sankyo’s [fam]-trastuzumab deruxtecan demonstrated an impressive 14.8-month median duration of response and 16.4-month median progression-free survival WILMINGTON, Del ...